C4 THERAPEUTICS INC (CCCC)
Health Care · Biotechnology · NASDAQ
C4 Therapeutics is a clinical-stage biotechnology company leveraging its TORPEDO platform to develop targeted protein degraders for the treatment of oncology and inflammatory diseases.
What C4 THERAPEUTICS INC does
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD) to create small-molecule medicines. Its proprietary TORPEDO platform is used to design and optimize protein degraders that harness the body's natural protein destruction process to address unmet needs in oncology, inflammation, neuroinflammation, and neurodegeneration. Its lead clinical candidate, cemsidomide, is an oral IKZF1/3 degrader being evaluated for multiple myeloma.
Recent developments
In April 2026, the company entered a collaboration with Roche to advance research in degrader-antibody conjugates (DACs), receiving a $20 million upfront payment. The company raised approximately $33.5 million in net proceeds through its ATM program in Q2 2026 to support cemsidomide development.
From C4 THERAPEUTICS INC's filing of 2026-08-11.
Themes: targeted protein degradation, oncology, multiple myeloma, inflammation and immunology, neurodegeneration, degrader-antibody conjugates
Fundamentals
- Price$2.85 as of 2026-10-08 close
- Market cap$351M as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+27.8% 2025-10-08 close $2.23 → 2026-10-08 close $2.85
- P/En/a negative earnings
- Net margin-292.1% FY2025, SEC XBRL
- ROE-40.9% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)-12.4% as of 2026-09-03
- Revenue CAGR (3y)+5.0% SEC XBRL
- Beta1.67 as of 2026-09-03
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How CCCC compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How C4 THERAPEUTICS INC looks technically
C4 THERAPEUTICS INC (CCCC) is trading 8.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 145 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 44.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 8.2% below its 200-day average, the long-term trend line — a long-term downtrend | -8.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.58 | $3.58 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.10 | $3.10 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 3.31. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 145 trading days ago — a "golden cross", a bullish long-term signal | 145 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with sellers in control | 25.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30) | 33.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($2.72 to $3.45) — its "stochastic" reading is 18 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 17.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 29 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.17 | $5.17 |
|---|---|---|
| From the 52-week high | it is 44.9% below its 52-week high (its highest price of the past year) | -44.9% |
| Above the 52-week low | it is 68.6% above its 52-week low (its lowest price of the past year) | +68.6% |
| Below the 52-week high | it is 44.9% below its highest point of the past year | 44.9% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $51.21 (set on 2021-09-23) | $51.21 |
| Given back of the 52-week move | over the past year its closes ranged ($1.71 to $4.67), and it has given back a bit over half of its rise from last year’s low — 61% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.75 to $2.84. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 61.5% |
| From the all-time high | it is 94.4% below its all-time high | -94.4% |
| Nearest price level | it is trading 0.9% above a support level at $2.83 — a price it turned at four times since 2025-09-05, most recently on 2025-12-03. Since 2024-10-08 it has 5 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.9% |
| All-time low | its lowest closing price on record is $1.06 (set on 2023-12-06) | $1.06 |
| Above the all-time low | it is 168.9% above its all-time low | +168.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 51st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2078 between its high and its low — about 7.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2078 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.74 and $3.61 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.74 – $3.18 – $3.61 |
| Typical daily range (% of price) | its price moves about 7.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.3% |
| Stretch from the 200-day average | it is trading 1.2 daily ranges below its 200-day average price (8.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.02× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.7% |
|---|---|---|
| Gap filled | a 2.0% gap up opened on 2026-10-05 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 3 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 20.8 percentage points (the stock lost 19.7% while the market gained 1.0%) | -20.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 35.8 percentage points (the stock lost 32.0% while the market gained 3.8%) | -35.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 17.1 percentage points (the stock gained 0.4% while the market gained 17.5%) | -17.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 12.8 percentage points (the stock gained 27.8% while the market gained 15.0%) | +12.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 27% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 12.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -27.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.37 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -15.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 21% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.59 — a volume-weighted average of daily closes over 42 sessions, not a true tick-by-tick VWAP. | -20.7% |
Head and shoulders, bearish — broke down · entry $3.13 · 87 sessions in
Price levels it has turned at before
CCCC last closed at $2.85 on 2026-10-08. Since 2024-10-08 it has turned at 5 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.83 | Support | 0.9% below the last close | turned there four times · 2025-09-05 to 2025-12-03 |
| $3.38 | Resistance | 18.5% above the last close | turned there three times · 2025-01-13 to 2026-08-03 |
| $2.29 | Support | 19.6% below the last close | turned there three times · 2025-03-24 to 2026-03-30 |
| $3.58 | Resistance | 25.6% above the last close | turned there three times · 2024-12-18 to 2026-09-17 |
| $1.95 | Support | 31.6% below the last close | turned there twice · 2025-03-11 to 2025-08-06 |
| $3.82 | Resistance | 34.0% above the last close | turned there four times · 2024-11-20 to 2026-03-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $3.31.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $3.05 and $3.23 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 2 trading days, since 2026-10-07.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Printed a bullish engulfing pair · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.14 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$13.33 range $7.00 – $30.00; median $11.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CCCC
- Consensus EPS estimate-$0.2225 next reporting period, as of 2026-10-07
- Estimate change, 30 days+$0.0075 from -$0.23, on 2026-09-02, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with a history of significant losses and no current revenue from product sales.","Reliance on the successful development and regulatory approval of its lead clinical-stage candidates, primarily cemsidomide.","Substantial, increasing operating expenses expected as clinical trials advance."]
What changed in the latest 10-Q
AI-assisted comparison of CCCC's 10-Q filed 2026-08-11 against the prior one filed 2026-05-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds: In June 2026, at the EHA 2026 Congress, the company presented updated data from the Phase 1 trial of cemsidomide in combination with dexamethasone in MM, stating the analysis demonstrated a generally well-tolerated safety profile and compelling anti-myeloma activity.
- Newer filing adds specific timeline guidance: Enrollment for the Phase 2 MOMENTUM trial is expected to be complete in the first quarter of 2027 with initial investigator-assessed overall response rate data expected in the second half of 2027.
- Newer filing adds specific detail on the Phase 1b cemsidomide/dexamethasone/elranatamab trial: enrollment is ongoing, with an update on dose escalation progress expected in the second half of 2026 and data from all cohorts expected in mid-2027.
- Newer filing adds detail on the planned additional Phase 1b trial: it will evaluate cemsidomide in two combination cohorts (cemsidomide, dexamethasone, and daratumumab, or cemsidomide, dexamethasone, and carfilzomib), with the goal of characterizing cemsidomide's dose and safety with approved standard of care MM therapies.
- Newer filing adds a statement regarding CFT8919: based on the evolving treatment landscape for EGFR mutated NSCLC, capital priorities, and available clinical data to date, the company will not advance CFT8919 into the next phase of clinical development outside of Greater China at this time.
- Removed:
- Older filing includes a 'Recent Developments' section with three bullet points (April 2026 Roche Agreement, March 2026 first patient dosed in Phase 1b cemsidomide/dexamethasone/elranatamab trial, February 2026 first patient dosed in Phase 2 MOMENTUM trial) that is absent in the newer filing.
- Older filing describes September 2025 Phase 1 data for cemsidomide in MM (generally well-tolerated, robust IKZF1/3 degradation and T-cell activation, compelling anti-myeloma activity as measured by overall response rate and clinical benefit rate); this September 2025 data description is removed in the newer filing.
- Reworded:
- Older filing states cemsidomide is 'currently in clinical development for multiple myeloma, or MM' and refers to 'small molecule protein degraders'; newer filing omits the separate MM clinical development sentence and uses 'small-molecule protein degraders' (hyphenation change).
- Older filing states the additional Phase 1b trial would 'evaluate cemsidomide in additional combinations with approved multiple myeloma therapies'; newer filing specifies the two combination cohorts and the goal of characterizing dose and safety.
- Older filing describes CFT8919 development without a discontinuation statement; newer filing adds that the company will not advance CFT8919 outside of Greater China at this time.
- Older filing's research and development expenses bullet refers to 'contract research organizations and other third parties' and 'third parties that manufacture our product candidates'; newer filing expands this to 'contract research organizations, or CROs, and other third parties' and 'contract manufacturing organizations, or CMOs, that manufacture our product candidates'.
- Older filing includes the sentence 'We expense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our condensed consolidated financial statements as prepaid or accrued research and development expenses. Nonrefundable advance payments for goods or services to be received in the future for'; newer filing's corresponding text ends at 'specific tasks' (truncated).
- Notes:
- The newer filing text appears truncated at the end of the Research and development expenses section, preventing complete comparison of the final sentences.
Risk Factors
- Added:
- In the newer filing, net loss figures are reported for the six months ended June 30, 2026 and 2025 ($48.8 million and $52.3 million, respectively), replacing the prior three-month figures for March 31, 2026 and 2025.
- In the newer filing, accumulated deficit is stated as $787.5 million as of June 30, 2026, replacing the prior figure of $763.8 million as of March 31, 2026.
- In the newer filing, cash, cash equivalents, and marketable securities are stated as approximately $300.4 million as of June 30, 2026, replacing the prior figure of approximately $268.3 million as of March 31, 2026.
- In the newer filing, the cash runway estimate is stated as sufficient to fund planned operating expenses to the end of 2028.
- In the newer filing, a statement was added that holders have exercised Pre-Funded Warrants to purchase 15,695,500 shares of common stock as of June 30, 2026, and that no anticipated proceeds from potential exercise of remaining Pre-Funded Warrants, Class A Warrants, or Class B Warrants issued in the 2025 Offering are included in the cash runway estimate.
- Removed:
- In the older filing, a paragraph included details about the October 2025 sale of 21,895,000 Shares of common stock, Pre-Funded Warrants to purchase 28,713,500 shares, and Class A Warrants to purchase an aggregate of 50,608,500 shares of common stock, which is absent from the newer filing.
- In the older filing, a sentence following the accumulated deficit discussion listed activities required to become and remain profitable, including completing preclinical studies and clinical trials, discovering additional product candidates, establishing arrangements with third parties, procuring manufacturing, obtaining marketing approval, identifying collaborators, and completing development for collaboration partners, which is absent from the newer filing.
- The older filing section appears to end mid-sentence with '...Class A Warrants to purchase an aggregate of 50,608,500 shares of our common stock (or, for those invest'.
- Reworded:
- The newer filing changed the sentence describing failure to sustain profitability from 'Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue operations. A decline in the value of our company, or in the value of our common stock, could also cause you to lose all or part of your investment.' to '...which could materially impair our ability to raise capital or continue operations. This could cause a decline in the value of our company or our common stock and you may lose all or part of your investment.'
- Notes:
- The older filing text appears truncated at the end, so some later content from the older filing may not have been available for comparison.
- Only the Risk Factors section text provided was compared; any changes outside that section are not addressed.
- Both provided excerpts contain identical portions, but the newer filing excerpt itself appears truncated mid-sentence near the end.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CCCC — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CCCC as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 20,664,781
- Reported value $96,504,526
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CCCC's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CCCC had 40,189,287 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CCCC had 32.7% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 22.68 days to cover at the same settlement.
- Reported short interest (shares) 40,189,287
- Short interest (% of shares outstanding) 32.7%
- Prior settlement (shares) 37,413,259
- Reported change 7.42%
- Days to cover (reported) 22.68
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Arvinas (ARVN)
- Kymera Therapeutics (KYMR)
- Nurix Therapeutics (NRIX)
- Monte Rosa Therapeutics (GLUE)
- BioTheryX
- Foghorn Therapeutics (FHTX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CCCC vs…
C4 THERAPEUTICS INC is found in…
CCCC ranks in…
Frequently asked questions
What does C4 THERAPEUTICS INC (CCCC) do?
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD) to create small-molecule medicines. Its proprietary TORPEDO platform is used to design and optimize protein degraders that harness the body's natural protein destruction process to address unmet needs in oncology, inflammation, neuroinflammation, and neurodegeneration. Its lead clinical candidate, cemsidomide, is an oral IKZF1/3 degrader being evaluated for multiple myeloma.
What sector is C4 THERAPEUTICS INC (CCCC) in?
C4 THERAPEUTICS INC (CCCC) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are C4 THERAPEUTICS INC's (CCCC) competitors?
Notable peers of C4 THERAPEUTICS INC (CCCC) include Arvinas, Kymera Therapeutics, Nurix Therapeutics, Monte Rosa Therapeutics and BioTheryX. This peer set is informational only — not financial advice.
Is C4 THERAPEUTICS INC (CCCC) overbought or oversold right now?
C4 THERAPEUTICS INC (CCCC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 33, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CCCC come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.